Stem cell player moves to Mass.

The adult stem cell therapy developer AlloCure has moved from Salt Lake City all the way to Burlington, MA. Lean and mean with fewer than 10 workers, AlloCure also has a new CEO: Robert Brenner. "If we could develop a cell therapy for acute kidney injury, it would be a revolution," Brenner tells Xconomy. "People have been working on this for their entire professional careers." Story

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.